Bioniche Life Sciences Inc. Announces a Change to its Board of Directors

Bioniche Life Sciences Inc. (BNC.TO) (BNC.AX), a research-based, technology-driven Canadian biopharmaceutical company, today announced that one of its Directors - Mr. Nick Photiades - is stepping down from the Board of Directors.

Mr. Photiades had been the Senior Director, Life Sciences, Venture Capital Division with the Business Development Bank of Canada until his retirement in 2008, after which he became a management and strategic planning consultant. He joined the Bioniche Life Sciences Inc. Board of Directors in September, 2009.
"The Board of Directors and management of the Company wish to recognize and thank Mr. Photiades for his three years of contribution to the Company," said Mr. James Rae , Board Chairman, Bioniche Life Sciences Inc. " Mr. Photiades has been a thoughtful and articulate Director, who provided expertise in audit, legal, financing, deal-making and strategic planning. We wish him all the best in his future endeavours."

It has been decided that the Director position vacated by Mr. Photiades will not be filled at this time.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
SOURCE: Bioniche Life Sciences Inc.